From Genetic Engineering News by Julianna LeMieux
New and better instruments, from aspiring and established companies alike, made 2022 a banner year for next-generation sequencing
Today, researchers who sequence DNA have choices that they have not had before. The NGS industry has, in one year, grown from a few players to a crowded field. For the past decade, most of the sequencing around the world has been done on instruments made by Illumina, the San Diego-based company that has dominated the market. Others, like Pacific Biosciences (PacBio) and Oxford Nanopore Technologies (ONT), have earned their place on the podium. Still others have tried to enter the game, but never made it past the first round.
But 2022 may change that, with the emergence of new entrants to the industry and new products launched by the veteran companies. James Hadfield, PhD, senior director, epigenomics, oncology translational medicine, AstraZeneca, told GEN that 2022 was the best year for NGS since 2006.
